NT-0796

Ambroxol, a repurposed cough suppressant, shows potential as a disease-modifying therapy for Parkinson's by enhancing lysosomal function and clearing α-synuclein aggregates, with the GREAT trial currently evaluating its efficacy.

The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions.

Nerandomilast (BI 1015550) is a potent and selective phosphodiesterase 4B (PDE4B) inhibitor demonstrating potential for treating idiopathic pulmonary fibrosis (IPF).

RMC-6236, a non-covalent pan-RAS(ON) inhibitor developed by Revolution Medicines, targets previously 'undruggable' RAS mutants like G12V/D/A/S, G13X, and Q61X.